Fresenius Pours EUR 54 Million Into European Infusion Capacity as NutriChef Lands in Six Markets
Published on 09/28/2026 at 16:11 | Editorial boerse-global.de
Fresenius has quietly been building out the industrial backbone of its clinical nutrition and intravenous fluids business, committing EUR 54 million to expand European production capacity for infusion solutions. The healthcare group disclosed the outlay on Friday, confirming that the money has already been deployed across two of its key manufacturing sites.
In Kutno, Poland, the company brought an additional production line on stream to lift local output, while in Isola della Scala, Italy, it widened both manufacturing and warehousing infrastructure. The moves are designed to address demand in infusion therapy and to shore up supply chains within Europe. Modernizing and enlarging existing plants also gives Fresenius more room to maneuver when serving hospitals and care facilities.
Word of the investment came as the stock finished Friday's session at EUR 46.15, a gain of 0.9%. By Monday, the shares had picked up further ground, advancing 2.2% to EUR 47.15 alongside a broadly firm European healthcare sector. No company-specific catalyst drove that session's move, yet the stock now trades 5.7% above its 200-day moving average of EUR 44.61.
Product Rollout and Pipeline Deals
On the product front, Fresenius Kabi launched NutriChef on 8 September, an enteral nutrition concept built on ingredients drawn from 21 plants and offered in three variants for medical use. The rollout spanned six European countries simultaneously, among them Germany, Switzerland, the Netherlands and three Scandinavian nations.
Should investors sell immediately? Or is it worth buying Fresenius?
The expansion efforts follow other operational strides. On 19 September, mAbxience — a unit majority-owned by Fresenius — signed a wide-ranging agreement with Sandoz covering licensing, development, manufacturing and commercialization of a biosimilar candidate based on emicizumab for the treatment of haemophilia A. Under the arrangement, mAbxience handles development and production at sites in Spain and Argentina, while Sandoz secured exclusive global marketing rights everywhere except Argentina, Uruguay and Paraguay. Neither party disclosed financial terms.
Analyst Support and Reimbursement Clarity
Barclays threw its weight behind the stock on 16 September, reiterating an "Overweight" rating with a price target of EUR 57.50. Analyst Hassan Al-Wakeel pointed among other things to an anticipated 4.85% change rate for hospital service reimbursement in 2027. A day later, UBS reaffirmed its "Buy" call with a EUR 56 target, flagging further upside from current levels.
That 4.85% reimbursement figure had already been put on the table by the company itself earlier in the month, giving the hospital operator a firmer handle on medium-term revenue planning for its inpatient facilities.
Internal Reshuffling and a China Exit
Management is also pressing ahead with internal tidying. Effective 1 January 2027, services currently delivered to the hospital subsidiary will be folded directly into Helios Kliniken GmbH. Roughly 1,700 employees of Fresenius Health Services — which today counts more than 4,000 staff — will move under the Helios umbrella together with their respective entities. Fresenius Kabi separately reported an expansion of European production capacity aimed at strengthening healthcare supply resilience.
Over at dialysis subsidiary Fresenius Medical Care, Friday brought news of a strategic pullback in China. The company will halt both production and distribution of its 4008A haemodialysis system there, along with its peritoneal dialysis activities. FMC expects one-off costs of around EUR 110 million for the third quarter of 2026 tied to the decision.
Investors now have 4 November 2026 circled, when Fresenius reports its third-quarter 2026 results.
Ad
Fresenius Stock: New Analysis - 28 September
Fresh Fresenius information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
